ImmunoPrecise Antibodies Ltd. (IPA) has announced a collaboration with RIBOPRO to improve the discovery and development of therapeutic antibodies. The partnership will integrate RIBOPRO’s expertise in mRNA sequence optimisation and LNP-based delivery with IPA’s advanced B-cell screening, single-cell analysis, and AI-driven discovery workflows.
EVA Pharma, an Egyptian pharmaceutical company, has partnered with France’s DNA Script and Belgium’s Quantoom Biosciences to establish Africa’s first end-to-end mRNA production platform. The partnership was formalised through a Memorandum of Understanding (MoU) signed during the 2nd Vaccine and
TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, has entered into a non-exclusive License and Supply Agreement with Aldevron, a global CDMO specialising in the production of plasmid DNA, RNA, and proteins. This partnership aims to expand access to TriLink’s CleanCap
Afrigen Biologics, a South African biotechnology company, has been awarded a $6.2 million grant by the Coalition for Epidemic Preparedness Innovations (CEPI) to advance research into an mRNA-based vaccine for Rift Valley fever. The disease, typically transmitted by mosquitoes, has
“The market for lipid nanoparticles really exploded during COVID-19,” says Alexander Aust, LNP manufacturing expert. Alexander Aust, a consultant specialising in lipid nanoparticle (LNP) manufacturing, brings years of experience from companies like Sigma-Tau Pharmaceuticals and Exelead. His expertise spans from
EXO Biologics and its CDMO subsidiary, ExoXpert, innovators in exosome-based therapeutics and drug delivery solutions, has achieved a significant milestone with its subsidiary ExoXpert becoming the first European CDMO to receive Good Manufacturing Practice (GMP) certification. The certification, awarded by
VectorBuilder, providing end-to-end gene delivery services, has joined forces with Sartorius, an international partner in life science research and the biopharmaceutical industry, to expand their longstanding partnership. The newly announced strategic agreement is set to accelerate innovations in gene vector
Meiji Seika Pharma has announced its investment in ARCALIS, a joint venture focused on the development and manufacturing of mRNA vaccines and pharmaceuticals. This collaboration aims to bolster the production of mRNA vaccines in Japan, ensuring faster and more reliable
SyVento Biotech, a contract development and manufacturing organisation (CDMO), has announced the opening of its new mRNA manufacturing facility in Poland. This state-of-the-art site, spanning over 7,000 m², includes lab and production areas, offices, and shared spaces. It marks a
BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), has announced a partnership with Centivax, Inc. The collaboration aims to develop Centivax’s universal influenza vaccine, Cent-Flu, which utilises a proprietary mixture of 22 unique mRNA transcripts
